Innovations in Biotechnology Part 7

Tham khảo tài liệu 'innovations in biotechnology part 7', kỹ thuật - công nghệ, cơ khí - chế tạo máy phục vụ nhu cầu học tập, nghiên cứu và làm việc hiệu quả | Translating 2A Research into Practice 171 satisfactory for short-term applications antibody intravenous infusion is not appropriate in many long-term treatments. Fang et al. 2007 describe a recombinant adeno-associated virus rAAV gene delivery system that allows regulated long-term expression of native fulllength mAbs in vivo. In this study a F2A sequence adjacent to a furin cleavage site AK RKRR was used to link the antibody heavy and light chain sequences. Notably the gene expression system included a rapamycin-regulated promoter that can be used to stop mAb production if treatment needs to be terminated. This system potentially offers patients a lifelong mAb therapy that requires only a single administration of an rAAV vector. Cytotoxic T-lymphocyte-associated antigen CTLA-4 also known as CD152 is a co-inhibitory molecule that functions to regulate T-cell activation. Antibodies that block the interaction of CTLA-4 with its ligands CD80 B7-1 and CD86 B7-2 can enhance immune responses including anti-tumour immunity for a brief review see Chambers et al. 2001 . Granulocyte-macrophage colony-stimulating factor GM-CSF is a bone marrow growth factor for APCs which has also been shown to enhance anti-tumour immune responses. Both preclinical animial models and early clinical development indicate synergy between GM-CSF tumour cell vaccination and CTLA-4 blockade Hurwitz et al. 2000 Hodi et al. 2003 Quezada et al. 2006 . To avoid anti-CTLA-4 side effects tumour cell lines expressing the full-length F2A anti-CTLA-4 mAb in addition to GM-CSF were administered locally at the immunization site Simmons et al. 2008 . Preliminary results suggest that the delivery of mAbs or proteins locally from immunotherapy cells should prove useful based on promising anti-tumour responses and the reduction of toxicity or adverse immune events associated with systemic exposure. Cytokines and immunotherapy The cytokine Interleukin-12 IL-12 is a growth and maturation factor acting on both

Không thể tạo bản xem trước, hãy bấm tải xuống
TÀI LIỆU LIÊN QUAN
69    594    52
TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.